WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis, with strong evidence for involvement of the alternative complement pathway (AP) in its pathogenesis, but no currently approved therapies specifically target the complement-mediated inflammatory process. Iptacopan binds to Factor B and inhibits the AP, leaving direct signaling from the lectin and classical pathways intact. The Phase 3 APPLAUSE-IgAN study is evaluating the efficacy and safety of iptacopan vs placebo on top of optimized supportive therapy in patients with IgAN.